Scientific development and product improvement must rely on testing and feedback from objective third party scientists. Following are several of the leading cognitive function researchers with a broad base of clinical experience. Brain Research Labs is proud to have such "brain power" involved in testing, validating and improving its products and technology.
Con Stough, Ph.D.
Director of the Brain Sciences Institute
The clinical trial on Procera-AVH™ was conducted by Dr. Con Stough of the prestigious Brain Sciences Institute, Swinburne University of Technology, in Australia. Dr. Stough has published over 100 papers in peer reviewed journals.
The Brain Sciences Institute (BSI) is one of the leading cognitive drug and supplement test labs in the world. The principal aim of the Brain Sciences Institute (BSI) is to conduct high quality research in human neuro and cognitive sciences. This is accomplished with a multi-disciplinary team of researchers across several different disciplines and areas of expertise that include physicists, psychologists, psycho-physiologists, biophysicists and neuroscientists.
Under the direction of Dr. Stough, BSI has conducted clinical trials on a broad array of pharmaceutical drugs and nutritional supplements, using one of the most advanced, fully equipped neuro and cognitive science labs in the world.
Equipment and capabilities include expensive and state-of-the-art brain imaging machines, such as MRI, fMRI and MEG, electrical recordings, EEG and ERP, lab blood analysis of sensitive markers of gene expression, oxidative stress and aging, and neuro-psychological measures including the world’s most advanced and respected cognitive assessment technology from CDR (Cognitive Drug Research), used in 100s of clinical trials for multi-national pharmaceutical companies.
The staff at the BSI have an international research reputation in several areas: Clinical Psychology and Trauma; Brain Electrical Neuroimaging; Biological Basis of Intelligence and Psychological Assessment; Visual Disorders and Processes; the Human Health Effects of Mobile Phone Emissions; Illicit Drug Research; Emotional Intelligence; and Clinical Trials on Natural Pharmacological Compounds. In addition the Centre will continues to build a significant domestic and international research presence in multi-disciplinary areas relating to Biological and Clinical Psychology, Cognitive Neuroscience and Biological Psychiatry.
Keith Wesnes, Ph.D
President and founder of Cognitive Drug Research (CDR) in England
Keith Wesnes, Ph.D, president and founder of Cognitive Drug Research (CDR) in England. Dr. Wesnes has conducted over 500 cognitive clinical trials and written over 200 papers in peer reviewed journals.
The Cognitive Drug Research (CDR) cognitive tests were used to validate the positive effects of Procera AVH™ on memory and working memory, and focus and concentration in close to 100 clinical trial volunteers, age range 22-65.
CDR is the world’s leading provider of cognitive testing services for the pharmaceutical industry. The CDR computerized test battery is perhaps the most sensitive and comprehensive way to detect and quantify drug and nutraceutical induced changes in a broad range of cognitive parameters including attention (concentration), working memory and memory.
The CDR system is a simple to administer automated test system which can definitively identify either enhancements or impairments in cognitive function in any population in any clinical trial setting. The CDR system has been used in well over one thousand clinical test sites worldwide
Professor Andrew Scholey, BSc (Hons) PhD, CPsychol, AFBPsS
Dr. Scholey is director of the Centre for Human Psychopharmacology at Swinburne University, Melbourne. He is a leading international researcher into the neurocognitive effects of natural products, supplements and food components, having published over 100 peer-reviewed journal articles and numerous book chapters. He is Professor of Brain and Behavioural Sciences and co-director of the NICM Collaborative Centre for the Study of Natural Medicines and Neurocognition. In 1998, he established the Human Cognitive Neuroscience Unit at Northumbria University, UK and was the Unit’s director until joining the then Brain Sciences Institute at Swinburne University in 2007. Professor Scholey was also co-director of the UK’s Medicinal Plant Research Centre and remains as honorary director of Neurocognitive trials.
Andrew has been lead investigator in a series of studies into the human biobehavioural effects of natural products, and their neurocognition-enhancing and anti-stress/anxiolytic properties.
Professor Scholey has supervised over 20 PhDs and over 100 honours students. He is committed to the public dissemination of science with numerous appearances in the print, audiovisual and digital media.